Abstract

: The goal of the present study was to determine whether volumetric parameters such as metabolic tumor volume (MTV) and total lesion glycolysis (TLG) measured by sequential F-FDG PET/CT imaging could be used as prognostic factors in patients with locally advanced rectal cancer (LARC) who received preoperative concurrent chemoradiotherapy. A total 64 patients with LARC patients were included in the current study. All patients were evaluated by F-FDG PET/CT before and after 45 Gy of radiotherapy with concurrent oral capecitabine chemotherapy. Initial, second, and the percent changes ([INCREMENT], %) of semiquantitative and volumetric parameters were used to calculate recurrence-free survival (RFS) and overall survival (OS). The cutoff values of semiquantitative and volumetric parameters were determined by receiver operating characteristic curve analysis. The prognostic significance was assessed using univariate and multivariate Cox proportional hazard regression analysis. For RFS, American Joint Committee on Cancer (AJCC) stage (χ = 10.7, P = 0.002), surgical margin (+) (χ = 3.39, P = 0.037), lymphatic invasion (+) (χ = 6.8, P = 0.0078), RECIST (Response Evaluation Criteria in Solid Tumors) (χ = 46.3, P < 0.0001), SUVmax1 (χ = 10.1, P = 0.025), ΔSUVmax (χ = 20.4, P < 0.0001), ΔSUVmean (χ = 28.8, P < 0.0001), MTV1 (χ = 24.1, P < 0.0001), ΔMTV (χ = 27.4, P < 0.0001), TLG1 (χ = 21.9, P < 0.0001), TLG2 (χ = 23.3, P < 0.0001), and ΔTLG (χ = 55.6, P < 0.0001) are associated prognostic factors. For OS, AJCC stage (χ = 6.0, P = 0.021), surgical margin (+) (χ = 3.2, P = 0.042), lymphatic invasion (+) (χ = 3.8, P = 0.048), RECIST (χ = 10.4, P = 0.0015), ΔSUVmax (χ = 6.0, P = 0.013), ΔSUVmean (χ = 10.5, P = 0.0009), MTV1 (χ = 14.5, P = 0.0008), ΔMTV (χ = 14.7, P = 0.0002), TLG1 (χ = 15.8, P = 0.0002), TLG2 (χ = 13.5, P = 0.0006), and ΔTLG (χ = 17.5, P < 0.0001) are potent predictors. Multivariate Cox proportional hazard regression analyses revealed that the initial MTV (MTV1) and ΔTLG were the potent predictors for RFS and OS. Our data suggest that MTV on initial pretreatment F-FDG PET/CT and ΔTLG of sequential F-FDG PET/CT after preoperative concurrent chemoradiotherapy in LARC patients could provide prognostic information.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.